CBD “Significantly Reduces” Pain, Other Symptoms In Nail-Patella Syndrome Patients
The global market for cannabidiol (CBD) is booming. Several market analysis reports and sector projections demonstrate the buffet of opportunities for entrepreneurs, investors, and innovators in the CBD sector.
For example, a recent analysis by researchers with Research and Markets found that “the global hemp-derived cannabidiol market size was estimated to be USD 8.28 billion in 2023 and is expected to reach USD 46.25 billion by 2034 with a CAGR of 16.93% during the forecast period 2024-2034.”
A separate analysis by Wiseguy Research Consultants estimated that the cannabidiol extract market was worth “5.06 billion USD in 2023” and that the market is projected to be worth “from 6.16 billion USD in 2024 to 29.8 billion USD by 2032.”
A growing number of studies are finding that CBD helps suffering patients. One such study was recently conducted in France which found that orally administered CBD significantly reduces pain and other symptoms among patients suffering from nail-patella syndrome. Below is more information about the study and its findings via a news release from NORML:
Paris, France: Patients suffering from nail-patella syndrome-induced pain report significant improvements in their health-related quality of life following CBD therapy, according to data published in the journal Nature: Scientific Reports. Nail-patella syndrome (NPS) is a rare genetic disease characterized by skeletal malformation and chronic pain.
French researchers assessed the safety and efficacy of CBD treatment in a cohort of 28 patients diagnosed with NPS. Study participants ingested pharmaceutical-grade synthetic CBD for three months.
Investigators reported: “Treatment (median dose of 900 mg/day) was associated with a significant reduction in pain intensity (mean score of 7.04 at initiation versus 4.04 at three months. … Health-related quality of life and other NPS-associated symptoms also improved in most patients. CBD treatment was well-tolerated and no elevations in liver enzyme levels were reported.”
The study’s authors concluded: “Oral treatment with synthetic CBD was associated with a significant reduction in pain in most of the patients with NPS included in our study and led to improvements in most of the NPS-associated symptoms analyzed. Hence, synthetic oral CBD appears to be a safe and effective treatment option for NPS-associated pain and may be an alternative to conventional analgesics for managing chronic pain in this pathology.”
Full text of the study, “Evidence for therapeutic use of cannabidiol for nail-patella syndrome-induced pain in a real-world pilot study,” appears in Nature: Scientific Reports. Additional information on cannabis and pain management is available from NORML’s publication, Clinical Applications for Cannabis & Cannabinoids.
